ALX Oncology Holdings
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ALX Oncology Holdings generated cash of -$130,364,000, which is less than the previous year. Cash used in financing activities reached the amount of $59,291,000 last year. Net change in cash is therefore -$26,416,000.
Cash Flow
| 2018 | -13.19M | -653K | 1K |
|---|---|---|---|
| 2019 | -14.24M | -353K | 15.35M |
| 2020 | -38.28M | 610K | 462.88M |
| 2021 | -68.10M | -4.92M | 2.47M |
| 2022 | -89.22M | -235.41M | 9.86M |
| 2023 | -130.36M | 44.65M | 59.29M |
ALXO Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 48.88M | 363.66M | 434.21M | 9.01M | 8.26M | 22.10M |
Operating activities | ||||||
Net income | -160.80M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 836K | 342K | 51K | 202K | 429K | 431K |
Stock-based compensation expense | 26.27M | 23.83M | 13.91M | 5.43M | 297K | 0 |
| Deferred income tax benefit | 26.27M | 23.83M | 13.91M | 5.43M | 297K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 536K | 396K | -932K |
Inventories | 0 | 0 | 0 | -536K | -396K | 0 |
Accounts payable | 458K | 4.50M | 3.29M | -3.74M | 2.97M | -269K |
Cash generated by operating activities | -130.36M | -89.22M | -68.10M | -38.28M | -14.24M | -13.19M |
Investing activities | ||||||
Purchases Of Investments | -246.62M | -376.78M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.27M | -1.42M | -4.92M | -31K | -353K | -653K |
Acquisitions Net | 0 | 233.98K | 0 | 641K | 0 | 0 |
Cash generated by investing activities | 44.65M | -235.41M | -4.92M | 610K | -353K | -653K |
Financing activities | ||||||
Common Stock Issued | 58.88M | 903K | 2.75M | 368.25M | 10K | 7K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 336K | 0 | 3K | 0 | -6K |
Repayments of term debt | -388K | 9.61M | -281K | -6.50M | 5.91M | 0 |
Cash used in financing activities | 59.29M | 9.86M | 2.47M | 462.88M | 15.35M | 1K |
Net Change In Cash | -26.41M | -314.77M | -70.55M | 425.20M | 755K | -13.84M |
Cash at end of period | 22.47M | 48.88M | 363.66M | 434.21M | 9.01M | 8.26M |
| Data source | Data source | Data source | Data source |